Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Melinta secures up to $135mm in loan from Vatera

Executive Summary

Antibiotics developer Melinta Therapeutics Inc. secured up to $135mm in a 5% convertible loan from Vatera Healthcare Partners and affiliates. The loan matures on January 6, 2025 and is convertible at the option of each lender into shares of preferred stock at an exercise price of $1.60 (the company's shares are currently averaging $1.48).
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • Private Placement

Related Companies